174 related articles for article (PubMed ID: 10748723)
21. Synthesis and evaluation of novel coumarin-based esterase-sensitive cyclic prodrugs of peptidomimetic RGD analogs with improved membrane permeability.
Wang B; Wang W; Camenisch GP; Elmo J; Zhang H; Borchardt RT
Chem Pharm Bull (Tokyo); 1999 Jan; 47(1):90-5. PubMed ID: 9987829
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and antiaggregatory activity of RGD-peptidomimetics based on 4-oxo-4-(piperazine-1-yl)butyric acid as Arg-mimetic.
Andronati SA; Krysko AA; Kabanov VM; Kabanova TA; Karaseva TL; Chugunov BM; Meshkova SB; Topilova ZM
Acta Pol Pharm; 2003; 60(5):375-81. PubMed ID: 15005421
[TBL] [Abstract][Full Text] [Related]
23. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides.
Gurrath M; Müller G; Kessler H; Aumailley M; Timpl R
Eur J Biochem; 1992 Dec; 210(3):911-21. PubMed ID: 1483474
[TBL] [Abstract][Full Text] [Related]
24. New potent and selective αvβ
Wu Z; Cheng X; Hong H; Zhao X; Zhou Z
Bioorg Med Chem Lett; 2017 May; 27(9):1911-1913. PubMed ID: 28351594
[TBL] [Abstract][Full Text] [Related]
25. Three-dimensional quantitative structure-activity relationship analyses of RGD mimetics as fibrinogen receptor antagonists.
Miyashita M; Akamatsu M; Hayashi Y; Ueno T
Bioorg Med Chem Lett; 2000 May; 10(9):859-63. PubMed ID: 10853647
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and antiaggregatory activity of antiflammin related peptides.
Marastoni M; Scaranari V; Salvadori S; Tomatis R; Spisani S; Traniello S
Farmaco; 1991 Nov; 46(11):1265-72. PubMed ID: 1811615
[TBL] [Abstract][Full Text] [Related]
27. Hybrid peptide containing RGDF (Arg-Gly-Asp-Phe) coupled with the carboxy terminal part of alpha 2-antiplasmin capable of inhibiting platelet aggregation and promoting fibrinolysis.
Udvardy M; Schwartzott D; Jackson K; McKee PA
Blood Coagul Fibrinolysis; 1995 Feb; 6(1):11-6. PubMed ID: 7795148
[TBL] [Abstract][Full Text] [Related]
28. Studies on the synthesis of cyclic pentapeptides as LHRH antagonists and the factors that influence cyclization yield.
Gao XM; Ye YH; Bernd M; Kutscher B
J Pept Sci; 2002 Aug; 8(8):418-30. PubMed ID: 12212805
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of cyclic peptides by ring-closing metathesis.
Reichwein JF; Versluis C; Liskamp RM
J Org Chem; 2000 Sep; 65(19):6187-95. PubMed ID: 10987958
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of a cyclic hexapeptide with sequence corresponding to murine tumor necrosis factor-(127-132) as a novel potential antitumor agent.
Sheh L; Cheng JY; Kuan YH; Chen CF
Int J Pept Protein Res; 1990 Aug; 36(2):104-8. PubMed ID: 2272746
[TBL] [Abstract][Full Text] [Related]
31. Circular dichroism studies of type III collagen mimetic peptides with anti- or pro-aggregant activities on human platelets.
Pêcher J; Pires V; Djaafri I; Da Nascimento S; Fauvel-Lafève F; Legrand C; Sonnet P
Eur J Med Chem; 2009 Jun; 44(6):2643-50. PubMed ID: 19056149
[TBL] [Abstract][Full Text] [Related]
32. Chemical synthesis and structural characterization of the RGD-protein decorsin: a potent inhibitor of platelet aggregation.
Polverino de Laureto P; Scaramella E; De Filippis V; Marin O; Doni MG; Fontana A
Protein Sci; 1998 Feb; 7(2):433-44. PubMed ID: 9521121
[TBL] [Abstract][Full Text] [Related]
33. Synthetic RGD peptides derived from the adhesive domains of snake-venom proteins: evaluation as inhibitors of platelet aggregation.
Lu X; Deadman JJ; Williams JA; Kakkar VV; Rahman S
Biochem J; 1993 Nov; 296 ( Pt 1)(Pt 1):21-4. PubMed ID: 8250845
[TBL] [Abstract][Full Text] [Related]
34. Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid.
Krysko AA; Chugunov BM; Malovichko OL; Andronati SA; Kabanova TA; Karaseva TL; Kiriyak AV
Bioorg Med Chem Lett; 2004 Nov; 14(22):5533-5. PubMed ID: 15482918
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands.
Salvati M; Cordero FM; Pisaneschi F; Melani F; Gratteri P; Cini N; Bottoncetti A; Brandi A
Bioorg Med Chem; 2008 Apr; 16(8):4262-71. PubMed ID: 18343671
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity studies of the s-echistatin inhibition of bone resorption.
Sato M; Garsky V; Majeska RJ; Einhorn TA; Murray J; Tashjian AH; Gould RJ
J Bone Miner Res; 1994 Sep; 9(9):1441-9. PubMed ID: 7817829
[TBL] [Abstract][Full Text] [Related]
37. Backbone modifications in cyclic peptides. Conformational analysis of a cyclic pseudopentapeptide containing a thiomethylene ether amide bond replacement.
Anwer MK; Sherman DB; Spatola AF
Int J Pept Protein Res; 1990 Oct; 36(4):392-9. PubMed ID: 2079394
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of all-L cyclic tetrapeptides using pseudoprolines as removable turn inducers.
Fairweather KA; Sayyadi N; Luck IJ; Clegg JK; Jolliffe KA
Org Lett; 2010 Jul; 12(14):3136-9. PubMed ID: 20565133
[TBL] [Abstract][Full Text] [Related]
39. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
Flouret G; Chaloin O; Borovickova L; Slaninová J
J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
[TBL] [Abstract][Full Text] [Related]
40. Cyclic pentapeptide analogs based on endomorphin-2 structure: cyclization studies using liquid chromatography combined with on-line mass spectrometry and tandem mass spectrometry.
Piekielna J; Kluczyk A; Perlikowska R; Janecka A
Peptides; 2014 May; 55():32-40. PubMed ID: 24525024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
